Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[(3R,4S)-4-hydroxy-3-methyl-2-oxohexyl]phosphonic acid is a potent small-molecule inhibitor of **1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR)**, also known as **IspC**. DXR is a rate-limiting enzyme in the **non-mevalonate (MEP) pathway** for isoprenoid biosynthesis, which is essential in many human pathogens, including *Plasmodium falciparum* (the causative agent of malaria) and *Mycobacterium tuberculosis*, but absent in humans. This compound acts as a **transition-state analog**, mimicking the intermediate formed during the conversion of 1-deoxy-D-xylulose 5-phosphate (DXP) to 2-C-methyl-D-erythritol 4-phosphate (MEP). Due to its high specificity for the bacterial and protozoal enzyme over human metabolic pathways, it has been investigated as a potential lead for the development of novel **antimalarial** and **antibacterial** agents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [(3R,4S)-4-hydroxy-3-methyl-2-oxohexyl]phosphonic acid.